CN Patent

CN103393596A — 一种甲硝唑的混悬液及其制备方法

Assigned to BEIJING ACTING PHARMACEUTICAL BIOTECHNOLOGY Co Ltd · Expires 2013-11-20 · 12y expired

What this patent protects

本发明涉及一种甲硝唑混悬液，按重量份数含有以下组分：水100份，甲硝唑0.5-10份，助悬剂硅酸镁铝和/或蔗糖10-60份，枸杞酸钠0.5-10份。本发明所制得的混悬液，比现有固体制剂易于服用，依从性好，生物利用度高；比现有的干混悬剂，使用方便；混悬液的制备工艺也较固体制剂和干混悬剂简单。

USPTO Abstract

本发明涉及一种甲硝唑混悬液，按重量份数含有以下组分：水100份，甲硝唑0.5-10份，助悬剂硅酸镁铝和/或蔗糖10-60份，枸杞酸钠0.5-10份。本发明所制得的混悬液，比现有固体制剂易于服用，依从性好，生物利用度高；比现有的干混悬剂，使用方便；混悬液的制备工艺也较固体制剂和干混悬剂简单。

Drugs covered by this patent

Metro I.V. In Plastic Container (METRONIDAZOLE) · Baxter

Patent Metadata

Patent number: CN103393596A
Jurisdiction: CN
Classification: —
Expires: 2013-11-20
Drug substance claim: No
Drug product claim: No
Assignee: BEIJING ACTING PHARMACEUTICAL BIOTECHNOLOGY Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.